Charles River Laboratories International (NYSE:CRL) Stock Rating Lowered by Wall Street Zen

Charles River Laboratories International (NYSE:CRL) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued on Saturday.

A number of other analysts have also recently issued reports on the stock. TD Cowen cut their target price on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating for the company in a research note on Monday, November 10th. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and increased their price target for the company from $142.00 to $195.00 in a report on Tuesday, September 9th. Evercore ISI raised their price objective on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, October 3rd. Baird R W raised Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 6th. Finally, Robert W. Baird upgraded Charles River Laboratories International from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $178.00 to $199.00 in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.38.

Charles River Laboratories International Stock Performance

CRL opened at $192.95 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. Charles River Laboratories International has a 12-month low of $91.86 and a 12-month high of $199.66. The business has a 50 day moving average of $177.40 and a 200-day moving average of $163.30. The stock has a market cap of $9.50 billion, a price-to-earnings ratio of -123.68, a PEG ratio of 6.87 and a beta of 1.63.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $990.43 million. During the same quarter in the prior year, the business earned $2.59 EPS. The firm’s revenue for the quarter was down .5% on a year-over-year basis. On average, equities research analysts expect that Charles River Laboratories International will post 9.36 earnings per share for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

A number of large investors have recently added to or reduced their stakes in the stock. Groupama Asset Managment acquired a new position in Charles River Laboratories International in the 3rd quarter valued at $416,000. CIBC Bancorp USA Inc. acquired a new position in Charles River Laboratories International in the third quarter valued at about $786,000. Danske Bank A S bought a new stake in Charles River Laboratories International during the third quarter worth about $4,070,000. Advisory Services Network LLC lifted its position in Charles River Laboratories International by 2.6% during the third quarter. Advisory Services Network LLC now owns 3,226 shares of the medical research company’s stock worth $505,000 after purchasing an additional 83 shares during the period. Finally, Castleark Management LLC acquired a new stake in Charles River Laboratories International during the third quarter worth about $4,892,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).